Publications by authors named "B Dervaux"
Article Synopsis
- The study evaluates the cost-effectiveness of tofacitinib as a second-line treatment after methotrexate failure for rheumatoid arthritis in France using a Markov model with 10,000 simulated patients.
- Introducing tofacitinib demonstrates cost savings of €1,679 per patient and increases quality-adjusted life years (QALYs) by 0.29 compared to traditional biologic treatments.
- This research is the first of its kind in France and agrees with findings from other countries, though it acknowledges limitations related to clinical trial data and focuses only on severe adverse effects.
Lower limb osteoarthritis (OA) often generates musculoskeletal pain causing functional impairment and decreasing mobility, autonomy, and quality of life. Patients with OA are commonly prescribed specific care for total hip arthroplasty or total knee arthroplasty (THA or TKA), when patients present symptoms that are refractory to nondrug treatments. Currently, when patients are discharged from orthopedic surgery, they are either referred to a rehabilitation department, or sent directly home with assistance such as remote monitoring by teleconsultation or a mobile application.
View Article and Find Full Text PDFObjectives: Self-administration consists in the administration of medications by the patient himself during his hospitalization. The order of October 10, 2022 (Arrêté du 10 octobre 2022 modifiant l'arrêté du 6 avril 2011) modified the April 6, 2011 regulation to allow and regulate self-administration practices in hospital units. This evolution opens new perspectives for patient autonomy.
View Article and Find Full Text PDFBackground: In young children, respiratory syncytial virus (RSV)-related bronchiolitis is typically more severe than other respiratory tract infections, with a greater need for oxygen therapy and respiratory support. Few studies have compared the cost of hospitalization with regard to virological status. The objective of this study was to compare the costs of hospitalization for RSV-positive vs.
View Article and Find Full Text PDFBackground: Respiratory syncytial virus (RSV) causes a considerable disease burden in young children globally, but reliable estimates of RSV-related costs and health-related quality-of-life (HRQoL) are scarce. This study aimed to evaluate the RSV-associated costs and HRQoL effects in infants and their caregivers in four European countries.
Methods: Healthy term-born infants were recruited at birth and actively followed up in four European countries.